var data={"title":"Miglitol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Miglitol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6583?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=miglitol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Miglitol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196614\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Glyset</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196639\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiabetic Agent, Alpha-Glucosidase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196617\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 2:</b> Oral: Initial: 25 mg 3 times daily at the start of each meal or may consider 25 mg once daily with gradual titration to 25 mg 3 times daily to minimize GI intolerance. After 4 to 8 weeks dose should be titrated to maintenance dose of 50 mg 3 times daily and continue for ~3 months; if glycosylated hemoglobin is not satisfactory, may further increase to maximum recommended dose: 100 mg 3 times daily. As tolerated, the lowest effective dose should be maintained.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Concomitant use with insulin and/or insulin secretagogues (eg, sulfonylurea):</i> Reduced dose of insulin and/or insulin secretagogues may be needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196618\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196619\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;25 mL/minute: No dosage adjustment necessary. Although miglitol is primarily excreted unchanged, the increased plasma levels in renal impairment are not expected to affect efficacy (clinical response is localized to the GI tract); however, the effects on adverse effects are unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;25 mL/minute or SCr &gt;2 mg/dL: Use not recommended (not adequately studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196620\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196594\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Glyset: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196580\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196598\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer orally at the start of each main meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196597\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2 (noninsulin-dependent, NIDDM):</b> Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8091996\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Glyset may be confused with Cycloset</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196587\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Flatulence (42%), diarrhea (29%), abdominal pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Dermatologic: Skin rash (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distention, gastrointestinal pain, intestinal obstruction, nausea, paralytic ileus, pneumatosis cystoides intestinalis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196601\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to miglitol or any of component of the formulation; diabetic ketoacidosis; inflammatory bowel disease; colonic ulceration; partial intestinal obstruction or predisposition to intestinal obstruction; chronic intestinal diseases associated with marked disorders of digestion or absorption or with conditions that may deteriorate as a result of increased gas formation in the intestine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196584\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI symptoms: Most common reactions are gastrointestinal related; incidence of abdominal pain and diarrhea tend to diminish considerably with continued treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: Hypoglycemia is unlikely to occur with miglitol monotherapy but may occur with combination therapy (eg, sulfonylurea, insulin). In patients taking miglitol, oral glucose (dextrose) should be used instead of sucrose (cane sugar) in the treatment of mild-to-moderate hypoglycemia since the hydrolysis of sucrose to glucose and fructose is inhibited by miglitol. Correction of severe hypoglycemia may require the use of either glucagon or IV glucose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Not recommended in severe impairment (serum creatinine &gt;2 mg/dL or CrCl &lt;25 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress-related states: It may be necessary to discontinue miglitol and administer insulin if the patient is exposed to stress (ie, fever, trauma, infection, surgery).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299711\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196589\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9538&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196603\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been reported in animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Kitzmiller 2008; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ACOG 2013; ADA 2018c; Blumer 2013; Kitzmiller 2008).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Agents other than miglitol are currently recommended to treat diabetes in pregnant women (ADA 2018c).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209281\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Miglitol is present in breast milk. The exposure to a breastfeeding infant is ~0.4% of a 100 mg maternal dose. Breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196592\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor therapeutic response by periodic blood glucose tests; hemoglobin A<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196595\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2018a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2018b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196583\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">In contrast to sulfonylureas, miglitol does not enhance insulin secretion; the antihyperglycemic action of miglitol results from a reversible inhibition of membrane-bound intestinal alpha-glucosidases which hydrolyze oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In patients with diabetes, this enzyme inhibition results in delayed glucose absorption and lowering of postprandial hyperglycemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196600\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Saturable at high doses: 25 mg dose: Completely absorbed; 100 mg dose: 50% to 70% absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.18 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;4% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 2-3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196602\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Glyset Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $329.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $362.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $427.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Miglitol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $206.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $227.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $267.92</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196604\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Darlibose (VN);</li>\n      <li>Diaban (TW);</li>\n      <li>Diamig (IN, IT);</li>\n      <li>Diaset (BD);</li>\n      <li>Diastabol (AT, CH, CZ, DE, ES, FI, FR, GR, HN, IE, MX, NL, PL, PT, SE, SI);</li>\n      <li>Glitol (KR);</li>\n      <li>Laiping (CN);</li>\n      <li>Migbose (TW);</li>\n      <li>Plumarol (ES);</li>\n      <li>Seibule (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2013;122(2 Pt 1):406-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/23969827 /pubmed\" target=\"_blank\" id=\"23969827 \">23969827 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222382\"></a>American Diabetes Association (ADA). 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi: 10.2337/dc18-S011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/29222382/pubmed\" target=\"_blank\" id=\"29222382\">29222382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018c;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo; <i>Endocr Pract</i>, 2011, 17(Suppl 2):1-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/21474420/pubmed\" target=\"_blank\" id=\"21474420\">21474420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al, &quot;Diabetes in Older Adults: A Consensus Report,&quot; <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitzmiller JL, Block JM, Brown FM, et al, &quot;Managing Preexisting Diabetes for Pregnancy: Summary of Evidence and Consensus Recommendations for Care,&quot; <i>Diabetes Care</i>, 2008, 31(5):1060-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):S251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo; <i>Ann Intern Med</i>, 2012, 156(3):218-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/22312141/pubmed\" target=\"_blank\" id=\"22312141\">22312141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglitol-drug-information/abstract-text/15461903 /pubmed\" target=\"_blank\" id=\"15461903 \">15461903 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9538 Version 125.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F196614\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F196639\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F196617\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F196618\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F196619\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F196620\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196594\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F196580\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F196598\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F196597\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8091996\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196587\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196601\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196584\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299711\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F196589\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F196603\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6209281\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F196592\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F196595\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196583\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F196600\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F196602\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F196604\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9538|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=miglitol-patient-drug-information\" class=\"drug drug_patient\">Miglitol: Patient drug information</a></li></ul></div></div>","javascript":null}